Español
India
Italiano
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Neuraxis
(AMEX:NRXS)
Intraday
$2.92
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$2.92
0
[0.00%]
At close: Jun 10
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Neuraxis Stock (AMEX:NRXS)
Neuraxis Stock (AMEX: NRXS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, June 07, 2024
NeurAxis Submits To FDA For Expansion Of IB-Stim Label; Provides Compliance With NYSE Guidelines
Benzinga Newsdesk
Wednesday, May 22, 2024
Neuraxis Q1 2024 GAAP EPS $(0.32) Up From $(1.18) YoY, Sales $646.635K Miss $2.229M Estimate
Benzinga Newsdesk
Thursday, May 16, 2024
NeurAxis Announces Publication Of Medical Policy Coverage For Percutaneous Electrical Nerve Field Stimulation With A Blue Cross Blue Shield License In FL
Benzinga Newsdesk
Tuesday, April 23, 2024
NeurAxis Announces New Medical Policy Coverage In North Dakota
Benzinga Newsdesk
Tuesday, April 09, 2024
Earnings Scheduled For April 9, 2024
Benzinga Insights
Monday, March 04, 2024
NeurAxis Announces Blue Cross And Blue Shield Of Kansas City Policy Coverage
Benzinga Newsdesk
Wednesday, January 31, 2024
NeurAxis Appoints Timothy Henrichs As CFO
Benzinga Newsdesk
Wednesday, December 20, 2023
NeurAxis, Inc. Issues Letter To Shareholders From Brian Carrico, President And Chief Executive Officer
Benzinga Newsdesk
Monday, November 20, 2023
Neuraxis Q3 EPS $(1.35) Down From $(1.14) YoY, Sales $477.46K Down From $618.80K YoY
Benzinga Newsdesk
Tuesday, November 14, 2023
NeurAxis Secures $3M Financing Through Preferred Stock Offering At $2.38 Per Share
Benzinga Newsdesk
Wednesday, November 08, 2023
NeurAxis Signs Exclusive Option Agreement With University Of Michigan For Innovative Gastrointestinal Device
Benzinga Newsdesk
Tuesday, September 26, 2023
NeurAxis Announces Results Of Comparative Study Of IB-Stim And Standard Medical Therapy In Adolescents With Functional Abdominal Pain Disorders
Benzinga Newsdesk
Thursday, September 21, 2023
Neuraxis Q2 EPS $(1.21) Down From $(0.87) YoY, Sales $646.00K Down From $682.60K YoY
Benzinga Newsdesk
Tuesday, September 12, 2023
Why CS Disco Are Trading Lower By 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin
NeurAxis Publishes Prospective Study Showing IB-Stim Improves Quality of Life of Adolescents with IBS
Benzinga Newsdesk
EXCLUSIVE: NeurAxis Tells Benzinga Co. Announces Publication Of Prospective Study Showing IB-Stim Improves Quality Of Life Of Adolescents With IBS
Benzinga Newsdesk
EXCLUSIVE: NeurAxis' Nerve Field Stimulation Tech Shows Improved Quality of Life of Adolescents Patients With Irritable Bowel Syndrome
Vandana Singh
Tuesday, August 29, 2023
EXCLUSIVE: Small MedTech Firm NeurAxis Targets $2B Market With Post-Concussion Therapy In Kids
Vandana Singh
EXCLUSIVE: NeurAxis Highlights Pediatric Post-Concussion Clinical Study 'A Prospective Study on the Effect of Auricular Percutaneous Electrical Nerve Field Stimulation'
Benzinga Newsdesk
Thursday, August 17, 2023
NeurAxis Announces Over $8M In IB-Stim Revenue
Happy Mohamed
Wednesday, August 09, 2023
Neuraxis Shares Resumed Trade
Happy Mohamed
Neuraxis Shares Halted On Circuit Breaker To The Upside
Happy Mohamed
Neuraxis Shares Resume Trade
Happy Mohamed
Neuraxis Shares Now Trading, Open At $6.50/Share; IPO Priced At $6/Share; Shares Halted On Circuit Breaker To The Downside
Happy Mohamed
NeurAxis Announces Pricing Of $6.592M Initial Public Offering Of 1,098,667 Shares Of Common Stock At An Price Of $6/Share
Happy Mohamed